Skip to Content
Morningstar

CSPC Pharmaceutical Group Ltd 01093

Morningstar Rating
Unlock
Stock XHKG Rating as of
HKD 6.76 +0.05 (0.75%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

CSPC: A Leading Chinese Pharmaceutical Company With Diversified Pipeline Portfolios

Yurou Zheng

CSPC is one of the largest and oldest pharmaceutical companies in China. Anchored by its nervous system business segment due to its flagship drug NBP, CSPC has a portfolio of innovative and generic drugs covering a wide range of diseases. NBP is a Class 1 new chemical drug for acute ischemic stroke. Class 1 drugs under the Chinese classification system are innovative drugs that have never been marketed globally. Thanks to its portfolio breadth, CSPC has been growing its revenue with a 10-year historical compounded annual growth rate of 25.0%, exceeding GDP growth.

Read Full Report

Price vs Fair Value

View History
01093 is trading at a 13% discount.
Price
HKD 6.76
Fair Value
HKD 4.90
Uncertainty
High
1-Star Price
HKD 11.66
5-Star Price
HKD 9.27
Economic Moat
Wfmywk
Capital Allocation
Hycmkgfh

Bulls Say, Bears Say

Bulls

Lack of generic drug substitutes for NBP which allows NBP to continue to bring in more revenue as an off-patent drug.

Bears

NBP’s generic drug entry turns out to be earlier than we expected, leading to a significant revenue decrease in the next three years.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 01093 is a good fit for your portfolio.
Get 7 Days Free

Trading Information

Previous Close Price
HKD 6.71
Day Range
HKD 6.65–6.79
52-Week Range
HKD 5.20–8.25
Bid/Ask
HKD 6.75 / HKD 6.76
Market Cap
HKD 80.42 Bil
Volume/Avg
39.7 Mil / 39.8 Mil

Key Statistics

Price/Earnings (Normalized)
11.58
Price/Sales
2.31
Dividend Yield (Trailing)
3.70%
Dividend Yield (Forward)
4.14%
Total Yield
3.97%

Company Profile

CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C, antibiotics, and a caffeine series.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Value
Total Number of Employees
23,500
Website
https://www.cspc.com.hk

Competitors

Valuation

View More
Metric
01093
01801
01177
Price/Earnings (Normalized)
 11.58—18.79
Price/Book Value
 2.205.411.61
Price/Sales
 2.319.291.84
Price/Cash Flow
 10.08—8.01
Price/Earnings
01093
01801
01177

Financial Strength

Metric
01093
01801
01177
Quick Ratio
 2.322.590.90
Current Ratio
 2.633.001.05
Interest Coverage
 276.31−15.2011.55
Quick Ratio
01093
01801
01177

Profitability

Metric
01093
01801
01177
Return on Assets (Normalized)
 14.29%−2.75%4.02%
Return on Equity (Normalized)
 19.78%−5.12%8.61%
Return on Invested Capital (Normalized)
 17.91%−5.63%5.53%
Return on Assets
01093
01801
01177
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Drug Manufacturers - General Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
LLY
Eli Lilly and CoPpfmbpxwkxCdhvb$698.5 Bil
JNJ
Johnson & JohnsonRqlwgmwstTvxct$359.2 Bil
MRK
Merck & Co IncRppgvnytjMmlf$323.0 Bil
ABBV
AbbVie IncBywfzmslvYcc$289.2 Bil
AZN
AstraZeneca PLC ADRMlcmhfqbpYthfz$236.3 Bil
NVS
Novartis AG ADRLjztwcqmkJtch$197.3 Bil
RHHBY
Roche Holding AG ADRWqxythwlJlvl$192.5 Bil
AMGN
Amgen IncQbryqzyryVttr$167.0 Bil
PFE
Pfizer IncRkztkckqpYrvq$157.5 Bil
SNY
Sanofi SA ADRCtnlmvzgMwfz$122.3 Bil

Sponsor Center